Navigation Links
Allscripts Reports First Quarter 2008 Results
Date:4/30/2008

CHICAGO, April 30 /PRNewswire-FirstCall/ -- Allscripts, the leading provider of clinical software, connectivity and information solutions that physicians use to improve healthcare, today announced results for the three months ended March 31, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061005/ALLSCRIPTSLOGO-b)

Total revenue for the three months ended March 31, 2008 was $72.1 million, compared to $65.0 million for the same period last year, increasing by 11%. Revenue from software and related services for the three months ended March 31, 2008 was $58.6 million, compared to $51.2 million for the same period last year, increasing by approximately 14%.

Gross margin percentage was 50.0% for the first quarter of 2008, compared to 49.6% during the first quarter of 2007.

Net income for the three months ended March 31, 2008 was $0.1 million, or $0.00 per diluted share, compared to net income of $4.5 million, or $0.08 per diluted share, for the same period last year. Non-GAAP adjusted earnings for the three months ended March 31, 2008 were $5.0 million, or $0.09 per diluted share, compared to non-GAAP adjusted earnings of $6.4 million, or $0.11 per diluted share for the same period last year. Non-GAAP adjusted earnings for the three months ended March 31, 2008 and 2007 are comprised of net income giving effect to the add-back of acquisition-related amortization of $2.1 million and $1.5 million, respectively, or $0.04 and $0.02 per diluted share, respectively, net of tax, and total stock-based compensation expense of $1.2 million and $0.4 million, respectively, or $0.02 and $0.01 per diluted share, respectively, net of tax. Non-GAAP adjusted earnings for the three months ended March 31, 2008 also give effect to the add-back of transaction-related expenses of $1.6 million, or $0.03 per diluted share, net of tax. Please see "Explanation of Non-GAAP F 2,098 1,545

Transaction-related expenses (tax effected

at 39% for 2008) 1,621 -

Non-GAAP Adjusted Earnings $4,994 $6,405

Weighted average shares of common stock

outstanding used in computing diluted

non-GAAP adjusted earnings per share (a) 57,503 64,462

Non-GAAP Adjusted Earnings Per Share - diluted $0.09 $0.11

(a) Weighted average diluted shares for the three months ended March 31,

2007 include 7,329 common shares related to the Company's 3.5% Senior

Convertible Notes. Such shares were antidilutive for the three

months ended March 31, 2008. Interest expense, net of tax, totaling

$522 has been added back to net income for the net income per diluted

share calculation for the three months ended March 31, 2007.

inancial Measures" below for a discussion of non-GAAP adjusted earnings and earnings per share.

As of March 31, 2008, the Company had cash and marketable securities of $61.4 million.

"Allscripts delivered a solid sales performance during the first quarter of 2008 and we continue to make progress in deploying our TouchWorks electronic health record," said Glen Tullman, Chief Executive Officer of Allscripts. "When you consider that the first quarter is traditionally the slowest of the year, our sales performance demonstrates the strength of the market, the strength of the Allscripts brand, and the confidence our clients and prospects have in our company and our commitment to improving healthcare."

Explanation of Non-GAAP Financial Measures

Allscripts reports its financial results in accordance with generally accepted accounting principles, or GAAP. To supplement this information, Allscripts presents in this press release non-GAAP net income (and related per share amounts), which is a non-GAAP financial measure under Section 101 of Regulation G under the Securities Exchange Act of 1934, as amended. Non-GAAP net income consists of GAAP net income, excluding acquisition-related amortization, stock-based compensation expense under SFAS No. 123R, and transaction-related expenses, in each case net of any related tax benefit.

-- Acquisition-Related Amortization. Acquisition-related amortization

expense is a non-cash expense arising from the acquisition of

intangible assets in connection with acquisitions or investments.

Allscripts excludes acquisition-related amortization expense from

non-GAAP net income because it believes (i) the amount of such

expenses in any specific period may not directly correlate to the

underlying performance of Allscripts business operations and (ii) such

expenses can vary significantly between periods as a result of new

acquisitions and full amortization of previously acquired intangible

assets. Investors should note that the use of these intangible assets

contributed to revenue in the periods presented and will contribute to

future revenue generation and should also note that such expense will

recur in future periods.

-- Stock-Based Compensation Expense. Stock-based compensation expense is

a non-cash expense arising from the grant of stock awards to

employees. Allscripts excludes stock-based compensation expense from

non-GAAP net income because it believes (i) the amount of such

expenses in any specific period may not directly correlate to the

underlying performance of Allscripts business operations and (ii) such

expenses can vary significantly between periods as a result of the

timing of grants of new stock-based awards, including grants in

connection with acquisitions. Investors should note that stock-based

compensation is a key incentive offered to employees whose efforts

contributed to the operating results in the periods presented and are

expected to contribute to operating results in future periods and

should also note that such expense will recur in future periods.

-- Transaction-Related Expenses. Transaction-related expenses are fees

and expenses, including legal, investment banking and accounting fees,

incurred in connection with announced transactions. Allscripts

excludes transaction-related expenses from non-GAAP net income because

it believes (i) the amount of such expenses in any specific period may

not directly correlate to the underlying performance of Allscripts

business operations and (ii) such expenses can vary significantly

between periods.

Management also believes that non-GAAP net income (and related per share amounts) provides useful supplemental information to management and investors regarding the underlying performance of the Company's business operations and facilitates comparisons to our historical operating results. Management also uses this information internally for forecasting and budgeting as it believes that the measure is indicative of the Company's core operating results. Note however, that non-GAAP net income is a performance measure only, and it does not provide any measure of the Company's cash flow or liquidity. Non-GAAP financial measures are not in accordance with, or an alternative for, measures of financial performance prepared in accordance with GAAP and may be different from non-GAAP measures used by other companies. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with Allscripts results of operations as determined in accordance with GAAP. Investors and potential investors are encouraged to review the reconciliation of non-GAAP financial measures with GAAP financial measures contained within the attached condensed consolidated financial statements.

Allscripts will conduct a conference call on Wednesday, April 30, 2008 at 4:30 PM Eastern Time. The conference call can be accessed by dialing (800) 374-1376 and requesting the Allscripts earnings call, or via the Internet at http://www.allscripts.com. A recording of the conference call will be available for two weeks following the call at http://www.allscripts.com or by calling (800) 642-1687, ID # 44636385.

About Allscripts

Allscripts (Nasdaq: MDRX) is the leading provider of clinical software, connectivity and information solutions that physicians use to improve healthcare. The company's unique solutions inform, connect and transform healthcare, delivering improved care at lower cost. More than 40,000 physicians and thousands of other healthcare professionals in clinics, hospitals and extended care facilities nationwide utilize Allscripts to automate everyday tasks such as writing prescriptions, documenting patient care, managing billing and scheduling, and safely discharging patients, as well as to connect with key information and stakeholders in the healthcare system. To learn more, visit Allscripts at http://www.allscripts.com.

This news release may contain forward-looking statements within the meaning of the federal securities laws. Statements regarding future events, developments, the Company's future performance, as well as management's expectations, beliefs, intentions, plans, estimates or projections relating to the future are forward-looking statements within the meaning of these laws. These forward-looking statements are subject to a number of risks and uncertainties, some of which are outlined below. As a result, actual results may vary materially from those anticipated by the forward-looking statements. Among the important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are: the volume and timing of systems sales and installations; length of sales cycles and the installation process; the possibility that products will not achieve or sustain market acceptance; the timing, cost and success or failure of new product and service introductions, development and product upgrade releases; competitive pressures including product offerings, pricing and promotional activities; our ability to establish and maintain strategic relationships; undetected errors or similar problems in our software products; compliance with existing laws, regulations and industry initiatives and future changes in laws or regulations in the healthcare industry; possible regulation of the Company's software by the U.S. Food and Drug Administration; the possibility of product-related liabilities; our ability to attract and retain qualified personnel; our ability to identify and complete acquisitions, manage our growth and integrate acquisitions; maintaining our intellectual property rights and litigation involving intellectual property rights; risks related to third-party suppliers; our ability to obtain, use or successfully integrate third-party licensed technology; breach of our security by third parties; and the risk factors detailed from time to time in our reports filed with the Securities and Exchange Commission, including our 2007 Annual Report on Form 10-K available through the Web site maintained by the Securities and Exchange Commission at http://www.sec.gov. The Company undertakes no obligation to update publicly any forward-looking statement, whether as a result of new information, future events or otherwise.

Allscripts Healthcare Solutions, Inc.

Condensed Consolidated Balance Sheets

(amounts in thousands)

(Unaudited)

March 31, December 31,

Assets 2008 2007

Current assets:

Cash and cash equivalents $43,721 $43,785

Marketable securities 10,196 5,759

Accounts receivable, net 80,997 81,351

Deferred taxes, net 17,700 16,650

Inventories 6,300 4,178

Prepaid expenses and other

current assets 19,534 17,401

Total current assets 178,448 169,124

Long-term marketable securities 7,464 13,459

Fixed assets, net 21,209 18,238

Software development costs, net 25,509 24,115

Intangible assets, net 104,070 107,503

Goodwill 240,545 240,452

Other assets 4,498 5,252

Total assets $581,743 $578,143

Liabilities and Stockholders' Equity

Current liabilities:

Accounts payable $14,284 $15,911

Accrued liabilities 23,615 22,707

Accrued acquisition obligation - 8,946

Deferred revenue 55,589 45,940

Current portion of long-term debt 285 279

Other current liabilities - 274

Total current liabilities 93,773 94,057

Long-term debt 135,089 135,162

Deferred income taxes 8,236 6,179

Other liabilities 2,198 2,105

Total liabilities 239,296 237,503

Stockholders' equity 342,447 340,640

Total liabilities and

stockholders' equity $581,743 $578,143

Allscripts Healthcare Solutions, Inc.

Condensed Consolidated Statements of Operations

(amounts in thousands, except per-share amounts)

(Unaudited)

Three Months Ended

March 31,

2008 2007

Revenue:

Software and related services $58,618 $51,240

Prepackaged medications 9,595 10,229

Information services 3,876 3,553

Total revenue 72,089 65,022

Cost of revenue:

Software and related services 25,919 22,382

Prepackaged medications 7,613 8,308

Information services 2,516 2,059

Total cost of revenue (a) 36,048 32,749

Gross profit 36,041 32,273

Operating expenses:

Selling, general and administrative

expenses (b) 31,393 22,374

Amortization of intangibles 3,439 2,576

Income from operations 1,209 7,323

Interest expense (1,644) (933)

Interest income 570 1,049

Other expense, net (5) (12)

Income before income taxes 130 7,427

Income taxes (50) (2,960)

Net income $80 $4,467

Net income per share - basic $0.00 $0.08

Net income per share - diluted $0.00 $0.08

Weighted average shares of common stock

outstanding used in computing basic net

income per share 56,503 54,639

Weighted average shares of common stock

outstanding used in computing diluted net

income per share (c) 57,503 64,462

(a) Includes stock-based compensation of $347 and $82 for the three

months ended March 31, 2008 and 2007, respectively.

(b) Includes stock-based compensation of $1,612 and $574 for the three

months ended March 31, 2008 and 2007, respectively.

(c) Weighted average diluted shares for the three months ended March 31,

2007 include 7,329 common shares related to the Company's 3.5%

Senior Convertible Notes. Such shares were antidilutive for the

three months ended March 31, 2008. Interest expense, net of tax,

totaling $522 has been added back to net income for the net income

per diluted share calculation for the three months ended March 31,

2007.

Allscripts Healthcare Solutions, Inc.

Reconciliation of Non-GAAP Adjusted Earnings and Non-GAAP Adjusted

Earnings Per Share

(amounts in thousands, except per-share amounts)

(Unaudited)

Three Months Ended

March 31,

2008 2007

Net Income $80 $4,467

Stock compensation expense (tax effected

at 39% for 2008 and 40% for 2007) 1,195 393

Deal-related amortization (tax effected at

39% for 2008 and 40% for 2007)
'/>"/>

SOURCE Allscripts Healthcare Solutions, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Allscripts Named to FORTUNE 100 Fastest-Growing Companies List
2. West Penn Allegheny Health System Selects Electronic Health Record From Allscripts
3. Sandia National Laboratories Selects Allscripts Electronic Health Record and Practice Management for Employee Health Center
4. Allscripts Featured in Microsoft HealthVault Worldwide Launch
5. Lakeside Systems Selects Allscripts Electronic Health Record for 100 Physicians
6. Allscripts to Announce Third Quarter 2007 Results on November 8th
7. Allscripts Reports Third Quarter 2007 Results
8. Allscripts Electronic Health Record Ranked No. 1 by Physician Groups in KLAS Year-End Report
9. Allscripts Adds TeamPraxis Quality Reporting Software for Electronic Health Records
10. ProHealth Physicians Selects Allscripts Electronic Health Record and Practice Management for 240 Providers
11. Mankato Clinic Selects Allscripts Electronic Health Record
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
(Date:6/24/2016)... ... 24, 2016 , ... Puradigm® & Innovative Solutions today announced ... and processing operations at its production facility, and opened its first two dispensaries ... manufacturer of a complete system of proactive air and surface purification solutions for ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: